Literature DB >> 22002839

[Considerations about the efficacy of psychopharmacological drugs].

S Leucht1, S Heres, J M Davis.   

Abstract

Current systematic reviews yielded relatively small efficacy effect sizes of different psychopharmacological agents compared to placebo. It seems that these effect sizes have decreased compared to earlier meta-analyses. We speculate about factors explaining the decrease of effect size such as lower methodological requirements for earlier randomised controlled trials, but in particular enormous methodological problems of current trials such as chronic patient populations, exclusion of severely ill patients by the protocols, sponsoring by the pharmaceutical industry and so-called professional patients. A few examples from general medicine are used to illustrate that the effect sizes of other medications are often also surprisingly small. Psychotropic drugs are efficacious, but they need to be prudently applied according to evidence-based criteria.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22002839     DOI: 10.1007/s00115-011-3349-9

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  34 in total

1.  STREPTOMYCIN treatment of pulmonary tuberculosis.

Authors: 
Journal:  Br Med J       Date:  1948-10-30

2.  Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction.

Authors:  Victor C Lee; David C Rhew; Michelle Dylan; Enkhe Badamgarav; Glenn D Braunstein; Scott R Weingarten
Journal:  Ann Intern Med       Date:  2004-11-02       Impact factor: 25.391

Review 3.  Antidepressant drug effects and depression severity: a patient-level meta-analysis.

Authors:  Jay C Fournier; Robert J DeRubeis; Steven D Hollon; Sona Dimidjian; Jay D Amsterdam; Richard C Shelton; Jan Fawcett
Journal:  JAMA       Date:  2010-01-06       Impact factor: 56.272

4.  Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  1991-08

Review 5.  Amitriptyline for inpatients and SSRIs for outpatients with depression? Systematic review and meta-regression analysis.

Authors:  C Barbui; G Guaiana; M Hotopf
Journal:  Pharmacopsychiatry       Date:  2004-05       Impact factor: 5.788

6.  Selective publication of antidepressant trials and its influence on apparent efficacy.

Authors:  Erick H Turner; Annette M Matthews; Eftihia Linardatos; Robert A Tell; Robert Rosenthal
Journal:  N Engl J Med       Date:  2008-01-17       Impact factor: 91.245

7.  Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials.

Authors:  Corrado Barbui; Toshiaki A Furukawa; Andrea Cipriani
Journal:  CMAJ       Date:  2008-01-29       Impact factor: 8.262

Review 8.  Second-generation antipsychotics for schizophrenia: can we resolve the conflict?

Authors:  S Leucht; W Kissling; J M Davis
Journal:  Psychol Med       Date:  2009-04-01       Impact factor: 7.723

Review 9.  Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD).

Authors:  G M Soomro; D Altman; S Rajagopal; M Oakley-Browne
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

10.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Authors:  Colin Baigent; Lisa Blackwell; Rory Collins; Jonathan Emberson; Jon Godwin; Richard Peto; Julie Buring; Charles Hennekens; Patricia Kearney; Tom Meade; Carlo Patrono; Maria Carla Roncaglioni; Alberto Zanchetti
Journal:  Lancet       Date:  2009-05-30       Impact factor: 79.321

View more
  2 in total

Review 1.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

Review 2.  50 years of hurdles and hope in anxiolytic drug discovery.

Authors:  Guy Griebel; Andrew Holmes
Journal:  Nat Rev Drug Discov       Date:  2013-09       Impact factor: 84.694

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.